Showing results (251-260 of 266) with videos related to

Sort By:
Pageof 27
MMWR. Morbidity and Mortality Weekly Report|January 27, 2022
Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021Mark W Tenforde, Manish M Patel, Manjusha Gaglani, et al.
Medrxiv : the Preprint Server for Health Sciences|June 23, 2022
Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United StatesKatherine Adams, Jillian P Rhoads, Diya Surie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 8, 2022
Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United StatesNathaniel M Lewis, Wesley H Self, Manjusha Gaglani, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2021
Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United StatesMark W Tenforde, Manish M Patel, Adit A Ginde, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 6, 2024
Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024Kevin C Ma, Diya Surie, Adam S Lauring, et al.
Open Forum Infectious Diseases|January 25, 2023
Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021-April 2022Nathaniel M Lewis, Nancy Murray, Katherine Adams, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2022
Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United StatesMark W Tenforde, Wesley H Self, Yuwei Zhu, et al.
The Journal of Infectious Diseases|December 21, 2021
Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021Nathaniel M Lewis, Eric A Naioti, Wesley H Self, et al.
Medrxiv : the Preprint Server for Health Sciences|February 16, 2022
Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational StudyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
BMJ (Clinical Research Ed.)|March 10, 2022
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational studyAdam S Lauring, Mark W Tenforde, James D Chappell, et al.
Pageof 27